Lonza Group has acquired Micro-Macinazione, one of Europe’s leading contract manufacturers providing micronization of active ingredients for the pharmaceutical and fine chemical industries.
Micro-Macinazione has 120 employees and is based in Monteggio, Switzerland.
The acquisition of Micro-Macinazione creates the global leader in the field of micronization services by building on Lonza/Capsugel’s existing micronization clinical and commercial manufacturing capabilities that are based in Quakertown, US.
Lonza/Capsugel strengthened its micronization offering to customers in January 2016 when it acquired Powdersize and has since invested in significant additional capacity at this site which came on stream in early 2017.
Micronization via jet milling is an established technique for enhancing the overall bioavailability of drug products by reducing or controlling the particle size of the API. By improving bioavailability, lower drug doses can be prescribed, potentially reducing a patient’s side effects.
Lonza’s pharma & biotech customers are increasingly looking for external partners to help them assess early-stage compounds and to improve product design by using micronization and sub-micronization to address key challenges of active pharmaceutical ingredients (API) development. A key focus for the new combined business will be highly potent APIs (HPAPIs) where Micro-Macinaziones’ pilot to commercial scale HPAPI offerings and Lonza’s recent HPAPI capacity expansion at Quakertown, provide the capacity and expertise needed to serve this growing area of the pharmaceutical market.
Lonza Group has acquired Micro-Macinazione, one of Europe’s leading contract manufacturers providing micronization of active ingredients for the pharmaceutical and fine chemical industries.
Micro-Macinazione has 120 employees and is based in Monteggio, Switzerland.
The acquisition of Micro-Macinazione creates the global leader in the field of micronization services by building on Lonza/Capsugel’s existing micronization clinical and commercial manufacturing capabilities that are based in Quakertown, US.
Lonza/Capsugel strengthened its micronization offering to customers in January 2016 when it acquired Powdersize and has since invested in significant additional capacity at this site which came on stream in early 2017.
Micronization via jet milling is an established technique for enhancing the overall bioavailability of drug products by reducing or controlling the particle size of the API. By improving bioavailability, lower drug doses can be prescribed, potentially reducing a patient’s side effects.
Lonza’s pharma & biotech customers are increasingly looking for external partners to help them assess early-stage compounds and to improve product design by using micronization and sub-micronization to address key challenges of active pharmaceutical ingredients (API) development. A key focus for the new combined business will be highly potent APIs (HPAPIs) where Micro-Macinaziones’ pilot to commercial scale HPAPI offerings and Lonza’s recent HPAPI capacity expansion at Quakertown, provide the capacity and expertise needed to serve this growing area of the pharmaceutical market.
No comments:
Post a Comment